Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review

Nigro, Maria Concetta; Marchese, Paola Valeria; Deiana, Chiara; Casadio, Chiara; Galvani, Linda; Federico, Alessandro Di; Giglio, Andrea De

doi:10.2147/lctt.s388047

Cited by 11 publications

(5 citation statements)

References 126 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, for a more accurate diagnosis, the unique characteristics of each cancer type must be identified. Representative successful cases include EGFR, KRAS, and BRAF mutations in lung cancer [11][12][13][14]. Recently, omics research on various characteristics has reached a level where it is possible to diagnose not only cancer but also types of cancer [15][16][17].…”

Section: Gastric Cancer and Liquid Biopsymentioning

confidence: 99%

Detection and Characterization of Methylated Circulating Tumor DNAs in Gastric Cancer

Seo,

Youn,

Bae

et al. 2024

Preprint

View full text Add to dashboard Cite

Gastric cancer is the 5th most common disease in the world and the 4th most common cause of death. It is diagnosed through esophagogastroduodenoscopy with biopsy, however there are limitations in finding lesions in the early stages. Recently, research has been actively conducted to use liquid biopsy to diagnose various cancers, including gastric cancer. Various substances derived from cancer are reflected in the blood. By analyzing these substances, it was expected that not only the presence or absence of cancer but also the type of cancer can be diagnosed. However, the amount of these substances is extremely small, and even these have various variables depending on the characteristics of the individual or the characteristics of the cancer. To overcome these, we collected methylated DNA fragments using MeDIP and compared them with normal plasma to characterize gastric cancer tissue or patient’s plasma. And we attempted to diagnose gastric cancer using the characteristics of cancer reflected in the blood through the cancer tissue and patient’s plasma. As a result, we confirmed that the consistency of common methylated fragments between tissue and plasma was approximately 41.2%, and found the possibility of diagnosing and characterizing cancer using the characteristics of the fragments through SFR and 5'end-motif analysis.

show abstract

Section: Gastric Cancer and Liquid Biopsymentioning

confidence: 99%

Detection and Characterization of Methylated Circulating Tumor DNAs in Gastric Cancer

Seo,

Youn,

Bae

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Mounting evidence has detailed the importance of the underlined molecular biology and cancer heterogeneity as critical factors for cancer prognosis and a response to anticancer treatment [ 105 , 106 ].…”

Section: Liquid Biopsy In Oncogene Addicted Advanced Nsclc: a Focus O...mentioning

confidence: 99%

Liquid Biopsy in NSCLC: An Investigation with Multiple Clinical Implications

Bertoli

Carlo

Basile

et al. 2023

IJMS

View full text Add to dashboard Cite

Tissue biopsy is essential for NSCLC diagnosis and treatment management. Over the past decades, liquid biopsy has proven to be a powerful tool in clinical oncology, isolating tumor-derived entities from the blood. Liquid biopsy permits several advantages over tissue biopsy: it is non-invasive, and it should provide a better view of tumor heterogeneity, gene alterations, and clonal evolution. Consequentially, liquid biopsy has gained attention as a cancer biomarker tool, with growing clinical applications in NSCLC. In the era of precision medicine based on molecular typing, non-invasive genotyping methods became increasingly important due to the great number of oncogene drivers and the small tissue specimen often available. In our work, we comprehensively reviewed established and emerging applications of liquid biopsy in NSCLC. We made an excursus on laboratory analysis methods and the applications of liquid biopsy either in early or metastatic NSCLC disease settings. We deeply reviewed current data and future perspectives regarding screening, minimal residual disease, micrometastasis detection, and their implication in adjuvant and neoadjuvant therapy management. Moreover, we reviewed liquid biopsy diagnostic utility in the absence of tissue biopsy and its role in monitoring treatment response and emerging resistance in metastatic NSCLC treated with target therapy and immuno-therapy.

show abstract

“…Examining CTCs DNA from tumors in circulation or extracellular vesicles derived from tumors released into the circulation from tumors and their metastatic locations constitutes the basis of liquid biopsies . Comprehensive reviews on CTCs, ctDNA, and extracellular vesicles have already been published [ 22 ]. Liquid biopsies, which analyze physiological fluids, can identify several cancer-indicative chemicals.…”

Section: Reviewmentioning

confidence: 99%

Unlocking Early Cancer Detection: Exploring Biomarkers, Circulating DNA, and Innovative Technological Approaches

Prasanth,

Alkhowaiter,

Sawarkar

et al. 2023

Cureus

View full text Add to dashboard Cite

Research and development improvements in early cancer diagnosis have had a significant positive impact on health. In the treatment and prevention of cancer, early detection is essential. In this context, biomarkers are essential because they offer important information on the state of cells at any particular time. Cells go through unique changes when they shift from a healthy condition to a malignant state, changes that appropriate biomarkers may pick up. Recent advancements have been made to identify and characterize circulating cancer-specific mutations in cell-free circulating DNA derived from tumors and tumor cells. A patient's delay between the time they first detect symptoms and the time they contact a doctor has been noted for many cancer forms. The tumor's location and features significantly impact the presentation of symptoms judged appropriate for early diagnosis. Lack of knowledge of the severity of the symptoms may be one cause for this delay. Our review is largely focused on the ongoing developments of early diagnosis in the study of biomarkers, circulating DNA for diagnosis, the biology of early challenges, early symptoms, liquid biopsies, detectable by imaging, established tumor markers, plasma DNA technologies, gender differences, and artificial intelligence (AI) in diagnosis. This review aims to determine and evaluate Indicators for detecting early cancer, assessing medical conditions, and evaluating potential risks. For Individuals with a heightened likelihood of developing cancer or who have already been diagnosed, early identification is crucial for enhancing prognosis and raising the likelihood of effective treatment.

show abstract

Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review

Cited by 11 publications

References 126 publications

Detection and Characterization of Methylated Circulating Tumor DNAs in Gastric Cancer

Detection and Characterization of Methylated Circulating Tumor DNAs in Gastric Cancer

Liquid Biopsy in NSCLC: An Investigation with Multiple Clinical Implications

Unlocking Early Cancer Detection: Exploring Biomarkers, Circulating DNA, and Innovative Technological Approaches

Contact Info

Product

Resources

About